Japan · Delayed Price · Currency is JPY Adeka Earnings Call Transcripts
Fiscal Year 2027
-
Sales and profit grew in Q1 FY2026, driven by chemicals and life science. Full-year forecasts and dividends were raised, with strong segment performance and ongoing investments in growth. Risks include raw material costs and market uncertainties.
Fiscal Year 2026
-
Net sales rose slightly year-over-year, but operating profit declined due to higher fixed costs. Guidance for full-year sales and profit was revised downward, with recovery expected in Q4, especially in polymer additives and semiconductor materials.
-
First-half FY2025 saw modest sales and profit growth, led by strong life science results offsetting weakness in chemicals and food. Full-year guidance is reaffirmed, with ongoing share buybacks and a stable dividend policy.
-
Q1 FY2025 saw higher sales and profits year-over-year, led by strong Life Science segment growth and resilient pricing, despite challenges in chemicals and food products. Full-year guidance remains unchanged, with a share buyback announced.
Fiscal Year 2025
-
Q1 saw YoY growth in sales and profit, with strong performance in Polymer Additives, Functional Chemicals, and Food Products, but a loss in Life Science. Full-year guidance was raised for the first half, with continued focus on semiconductors and environmental materials.